Palvella Therapeutics (NASDAQ:PVLA - Free Report) - Research analysts at HC Wainwright cut their Q1 2025 earnings per share (EPS) estimates for shares of Palvella Therapeutics in a research report issued to clients and investors on Tuesday, April 1st. HC Wainwright analyst A. Fein now forecasts that the company will post earnings of ($3.56) per share for the quarter, down from their prior estimate of ($0.86). HC Wainwright currently has a "Buy" rating and a $38.00 price target on the stock. The consensus estimate for Palvella Therapeutics' current full-year earnings is ($3.69) per share. HC Wainwright also issued estimates for Palvella Therapeutics' Q1 2025 earnings at ($3.56) EPS, Q2 2025 earnings at ($3.79) EPS, Q2 2025 earnings at ($3.79) EPS, Q3 2025 earnings at ($4.05) EPS, Q4 2025 earnings at ($4.33) EPS, Q4 2025 earnings at ($4.33) EPS, FY2025 earnings at ($15.73) EPS, FY2025 earnings at ($15.73) EPS, FY2026 earnings at ($12.67) EPS, FY2026 earnings at ($12.67) EPS, FY2027 earnings at ($13.80) EPS, FY2027 earnings at ($13.80) EPS, FY2028 earnings at ($8.72) EPS, FY2028 earnings at ($8.72) EPS and FY2029 earnings at ($5.23) EPS.
PVLA has been the topic of a number of other research reports. Canaccord Genuity Group reiterated a "buy" rating and issued a $39.00 price target on shares of Palvella Therapeutics in a research note on Wednesday, February 26th. Chardan Capital assumed coverage on Palvella Therapeutics in a research report on Wednesday. They issued a "buy" rating and a $50.00 target price on the stock. Scotiabank began coverage on Palvella Therapeutics in a report on Friday, March 7th. They set a "sector outperform" rating and a $50.00 price target for the company. Stifel Nicolaus began coverage on Palvella Therapeutics in a research note on Wednesday, March 26th. They issued a "buy" rating and a $45.00 price target for the company. Finally, Cantor Fitzgerald started coverage on Palvella Therapeutics in a report on Wednesday, December 18th. They set an "overweight" rating for the company. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus target price of $44.43.
Read Our Latest Analysis on PVLA
Palvella Therapeutics Trading Down 10.0 %
Shares of NASDAQ:PVLA traded down $2.06 on Friday, hitting $18.45. The company had a trading volume of 32,906 shares, compared to its average volume of 65,965. The company has a market cap of $203.30 million, a PE ratio of -1.52 and a beta of 0.10. The stock's 50 day moving average is $21.93. Palvella Therapeutics has a 1-year low of $6.20 and a 1-year high of $29.27.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Citadel Advisors LLC acquired a new stake in shares of Palvella Therapeutics during the 4th quarter worth approximately $125,000. Toronto Dominion Bank bought a new position in shares of Palvella Therapeutics in the 4th quarter valued at $159,000. Geode Capital Management LLC acquired a new position in shares of Palvella Therapeutics during the 4th quarter worth $171,000. Cresset Asset Management LLC bought a new stake in shares of Palvella Therapeutics during the 4th quarter worth $251,000. Finally, Renaissance Technologies LLC acquired a new stake in Palvella Therapeutics in the fourth quarter valued at about $256,000. Institutional investors and hedge funds own 40.11% of the company's stock.
About Palvella Therapeutics
(
Get Free Report)
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.
Read More
Before you consider Palvella Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Palvella Therapeutics wasn't on the list.
While Palvella Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
